Illumina, Inc. $ILMN Shares Purchased by Capital International Inc. CA

Capital International Inc. CA boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 12.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 97,935 shares of the life sciences company’s stock after purchasing an additional 10,799 shares during the period. Capital International Inc. CA’s holdings in Illumina were worth $12,845,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of Illumina by 17.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after acquiring an additional 124,246 shares in the last quarter. Elo Mutual Pension Insurance Co acquired a new position in shares of Illumina during the 3rd quarter valued at $2,319,000. Caprock Group LLC acquired a new position in shares of Illumina during the 3rd quarter valued at $1,479,000. Capital World Investors lifted its holdings in shares of Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after acquiring an additional 3,331,542 shares in the last quarter. Finally, Nordea Investment Management AB lifted its holdings in shares of Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after acquiring an additional 911,843 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ILMN. Royal Bank Of Canada began coverage on shares of Illumina in a report on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price on the stock. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a report on Thursday, May 14th. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday. Citigroup lifted their target price on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Finally, Wall Street Zen lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Illumina has a consensus rating of “Hold” and a consensus target price of $138.38.

Insider Activity

In other news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $98,400.00. Following the completion of the sale, the insider owned 21,568 shares of the company’s stock, valued at approximately $3,450,880. The trade was a 2.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the sale, the director directly owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. The trade was a 7.67% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 1,002,371 shares of company stock worth $155,472,900. 2.90% of the stock is owned by corporate insiders.

Illumina Stock Performance

Shares of ILMN stock opened at $162.32 on Monday. Illumina, Inc. has a 12 month low of $82.44 and a 12 month high of $177.22. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a market capitalization of $24.56 billion, a P/E ratio of 29.51, a P/E/G ratio of 3.04 and a beta of 1.50. The company’s fifty day moving average price is $137.75 and its two-hundred day moving average price is $133.67.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the business posted $0.97 EPS. The firm’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, research analysts anticipate that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.